Advances in the treatment of neuronal ceroid lipofuscinosis

Dolan Sondhi, Jonathan B. Rosenberg, Benjamin G. Van De Graaf, Stephen M. Kaminsky, Ronald Crystal

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Neuronal ceroid lipofuscinoses (NCL) represent a class of neurodegenerative disorders typically characterized by cognitive and visual impairment, seizures, deterioration of motor skills and early mortality. There has been increased interest in developing therapies directed towards slowing the progression, and possibly preventing and reversing the impact of these disorders. Despite many challenges, including the presence of the blood-brain barrier which prevents access to the central nervous system (CNS) and the need to markedly remove accumulated debris throughout the CNS, many treatment modalities have been proposed, including enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications. Some therapies have demonstrated measures of success, and these have progressed to human clinical trials. Continued development of current therapies and discovery of newer approaches will be essential for success. Areas covered: The reader will be introduced to the 14 known NCLs, the current approach to therapies, the evidence for efficacy and the challenges to success both at the pre-clinical and clinical stage. This review corresponds to the literatures covering the years from 1968 to mid-2013. Expert opinion: Much progress has been made in the classification of this family of neurologic diseases, including the genetic basis and functional outcomes which have led to the evaluation of several therapeutic interventions. These include enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications, each of which has associated pros and cons. Successful therapies in the future may necessitate the combination of two or more therapeutic modalities.

Original languageEnglish
Pages (from-to)951-975
Number of pages25
JournalExpert Opinion on Orphan Drugs
Volume1
Issue number12
DOIs
Publication statusPublished - 1 Jan 2013
Externally publishedYes

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Enzyme Replacement Therapy
Diet Therapy
Therapeutics
Cell- and Tissue-Based Therapy
Genetic Therapy
Stem Cells
Central Nervous System
Drug Therapy
Motor Skills
Vision Disorders
Expert Testimony
Nervous System Diseases
Blood-Brain Barrier
Neurodegenerative Diseases
Seizures
Clinical Trials
Mortality

Keywords

  • Adeno-associated virus
  • Ceroid lipofuscinosis neuronal
  • Clinical trials
  • Gene therapy
  • Neuronal ceroid lipofuscinoses
  • Palmitoyl protein thioesterase-1
  • Tripeptidyl peptidase-1

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Advances in the treatment of neuronal ceroid lipofuscinosis. / Sondhi, Dolan; Rosenberg, Jonathan B.; Van De Graaf, Benjamin G.; Kaminsky, Stephen M.; Crystal, Ronald.

In: Expert Opinion on Orphan Drugs, Vol. 1, No. 12, 01.01.2013, p. 951-975.

Research output: Contribution to journalReview article

Sondhi, D, Rosenberg, JB, Van De Graaf, BG, Kaminsky, SM & Crystal, R 2013, 'Advances in the treatment of neuronal ceroid lipofuscinosis', Expert Opinion on Orphan Drugs, vol. 1, no. 12, pp. 951-975. https://doi.org/10.1517/21678707.2013.852081
Sondhi, Dolan ; Rosenberg, Jonathan B. ; Van De Graaf, Benjamin G. ; Kaminsky, Stephen M. ; Crystal, Ronald. / Advances in the treatment of neuronal ceroid lipofuscinosis. In: Expert Opinion on Orphan Drugs. 2013 ; Vol. 1, No. 12. pp. 951-975.
@article{25903634af0c493899066397775840e7,
title = "Advances in the treatment of neuronal ceroid lipofuscinosis",
abstract = "Introduction: Neuronal ceroid lipofuscinoses (NCL) represent a class of neurodegenerative disorders typically characterized by cognitive and visual impairment, seizures, deterioration of motor skills and early mortality. There has been increased interest in developing therapies directed towards slowing the progression, and possibly preventing and reversing the impact of these disorders. Despite many challenges, including the presence of the blood-brain barrier which prevents access to the central nervous system (CNS) and the need to markedly remove accumulated debris throughout the CNS, many treatment modalities have been proposed, including enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications. Some therapies have demonstrated measures of success, and these have progressed to human clinical trials. Continued development of current therapies and discovery of newer approaches will be essential for success. Areas covered: The reader will be introduced to the 14 known NCLs, the current approach to therapies, the evidence for efficacy and the challenges to success both at the pre-clinical and clinical stage. This review corresponds to the literatures covering the years from 1968 to mid-2013. Expert opinion: Much progress has been made in the classification of this family of neurologic diseases, including the genetic basis and functional outcomes which have led to the evaluation of several therapeutic interventions. These include enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications, each of which has associated pros and cons. Successful therapies in the future may necessitate the combination of two or more therapeutic modalities.",
keywords = "Adeno-associated virus, Ceroid lipofuscinosis neuronal, Clinical trials, Gene therapy, Neuronal ceroid lipofuscinoses, Palmitoyl protein thioesterase-1, Tripeptidyl peptidase-1",
author = "Dolan Sondhi and Rosenberg, {Jonathan B.} and {Van De Graaf}, {Benjamin G.} and Kaminsky, {Stephen M.} and Ronald Crystal",
year = "2013",
month = "1",
day = "1",
doi = "10.1517/21678707.2013.852081",
language = "English",
volume = "1",
pages = "951--975",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Advances in the treatment of neuronal ceroid lipofuscinosis

AU - Sondhi, Dolan

AU - Rosenberg, Jonathan B.

AU - Van De Graaf, Benjamin G.

AU - Kaminsky, Stephen M.

AU - Crystal, Ronald

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Introduction: Neuronal ceroid lipofuscinoses (NCL) represent a class of neurodegenerative disorders typically characterized by cognitive and visual impairment, seizures, deterioration of motor skills and early mortality. There has been increased interest in developing therapies directed towards slowing the progression, and possibly preventing and reversing the impact of these disorders. Despite many challenges, including the presence of the blood-brain barrier which prevents access to the central nervous system (CNS) and the need to markedly remove accumulated debris throughout the CNS, many treatment modalities have been proposed, including enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications. Some therapies have demonstrated measures of success, and these have progressed to human clinical trials. Continued development of current therapies and discovery of newer approaches will be essential for success. Areas covered: The reader will be introduced to the 14 known NCLs, the current approach to therapies, the evidence for efficacy and the challenges to success both at the pre-clinical and clinical stage. This review corresponds to the literatures covering the years from 1968 to mid-2013. Expert opinion: Much progress has been made in the classification of this family of neurologic diseases, including the genetic basis and functional outcomes which have led to the evaluation of several therapeutic interventions. These include enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications, each of which has associated pros and cons. Successful therapies in the future may necessitate the combination of two or more therapeutic modalities.

AB - Introduction: Neuronal ceroid lipofuscinoses (NCL) represent a class of neurodegenerative disorders typically characterized by cognitive and visual impairment, seizures, deterioration of motor skills and early mortality. There has been increased interest in developing therapies directed towards slowing the progression, and possibly preventing and reversing the impact of these disorders. Despite many challenges, including the presence of the blood-brain barrier which prevents access to the central nervous system (CNS) and the need to markedly remove accumulated debris throughout the CNS, many treatment modalities have been proposed, including enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications. Some therapies have demonstrated measures of success, and these have progressed to human clinical trials. Continued development of current therapies and discovery of newer approaches will be essential for success. Areas covered: The reader will be introduced to the 14 known NCLs, the current approach to therapies, the evidence for efficacy and the challenges to success both at the pre-clinical and clinical stage. This review corresponds to the literatures covering the years from 1968 to mid-2013. Expert opinion: Much progress has been made in the classification of this family of neurologic diseases, including the genetic basis and functional outcomes which have led to the evaluation of several therapeutic interventions. These include enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications, each of which has associated pros and cons. Successful therapies in the future may necessitate the combination of two or more therapeutic modalities.

KW - Adeno-associated virus

KW - Ceroid lipofuscinosis neuronal

KW - Clinical trials

KW - Gene therapy

KW - Neuronal ceroid lipofuscinoses

KW - Palmitoyl protein thioesterase-1

KW - Tripeptidyl peptidase-1

UR - http://www.scopus.com/inward/record.url?scp=84896715300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896715300&partnerID=8YFLogxK

U2 - 10.1517/21678707.2013.852081

DO - 10.1517/21678707.2013.852081

M3 - Review article

AN - SCOPUS:84896715300

VL - 1

SP - 951

EP - 975

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 12

ER -